HISOAR(SZ:002099) Zhi Tong Cai Jing·2025-12-29 08:21Core Viewpoint - The announcement highlights the initiation of the Phase II clinical trial for NWRD06, a novel nucleic acid drug developed by Nuo Wei Biotechnology, which targets liver cancer recurrence post-surgery and represents a significant advancement in cancer treatment [1][2]. Group 1: Clinical Development - The Phase II clinical trial for NWRD06 has officially started at the Chinese Academy of Medical Sciences Cancer Hospital, with the first subject enrolled and treated [1]. - NWRD06 is the world's first therapeutic nucleic acid drug targeting the specific liver cancer marker GPC3, entering Phase II clinical trials [1]. Group 2: Mechanism and Potential - NWRD06 operates by activating specific T-cell immunity to eliminate tumor cells, showcasing an innovative mechanism that could potentially expand its application to early-stage cancer treatment [1]. - The drug may also have the potential to be combined with existing treatments for advanced liver cancer, such as interventional therapies and immune checkpoint inhibitors like PD-1 inhibitors [1]. Group 3: Clinical Value - The Phase I clinical study of NWRD06 has been completed, demonstrating its core value in precisely identifying tumor cells and addressing micro-lesions that are inaccessible to surgical treatment, while sparing normal tissues [2]. - The successful initiation of the Phase II trial marks a significant step towards clinical application, potentially offering a safe and non-invasive option for preventing recurrence in liver cancer patients, thereby improving survival rates [2].